Our top pick for
Editas Medicine, Inc is a biotechnology business based in the US. Editas Medicine shares (EDIT) are listed on the NASDAQ and all prices are listed in US Dollars. Editas Medicine employs 235 staff and has a trailing 12-month revenue of around USD$90.7 million.
|52-week range||USD$14.01 - USD$99.95|
|50-day moving average||USD$61.3076|
|200-day moving average||USD$45.8447|
|Wall St. target price||USD$52.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.138|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$90.7 million|
|Gross profit TTM||USD$-67,264,000|
|Return on assets TTM||-15.59%|
|Return on equity TTM||-35.36%|
|Market capitalisation||USD$3.1 billion|
TTM: trailing 12 months
There are currently 9.8 million Editas Medicine shares held short by investors – that's known as Editas Medicine's "short interest". This figure is 9.1% up from 9.0 million last month.
There are a few different ways that this level of interest in shorting Editas Medicine shares can be evaluated.
Editas Medicine's "short interest ratio" (SIR) is the quantity of Editas Medicine shares currently shorted divided by the average quantity of Editas Medicine shares traded daily (recently around 3.1 million). Editas Medicine's SIR currently stands at 3.21. In other words for every 100,000 Editas Medicine shares traded daily on the market, roughly 3210 shares are currently held short.
However Editas Medicine's short interest can also be evaluated against the total number of Editas Medicine shares, or, against the total number of tradable Editas Medicine shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Editas Medicine's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Editas Medicine shares in existence, roughly 160 shares are currently held short) or 0.1567% of the tradable shares (for every 100,000 tradable Editas Medicine shares, roughly 157 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Editas Medicine.
Find out more about how you can short Editas Medicine stock.
We're not expecting Editas Medicine to pay a dividend over the next 12 months.
Over the last 12 months, Editas Medicine's shares have ranged in value from as little as $14.01 up to $99.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Editas Medicine's is 2.1195. This would suggest that Editas Medicine's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.